FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912389092> ?p ?o ?g. }

• W2912389092 abstract "Rituximab, a therapeutic anti-CD20 monoclonal antibody, is effective against B-cell malignancies, when combined with chemotherapy, such as cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP therapy). However, in case of 30-40% patients the resistance to rituximab-based therapy appears to be a serious concern. One of the major mechanisms of resistance relies on the reduced level of CD20 antigen on the surface of tumor B-cells. While exploring the molecular mechanisms affecting the level of CD20, we found that transcription factor FOXO1 is a negative regulator of MS4A1 expression, the gene encoding CD20 antigen. Using the CRISPR/Cas9 genome-editing technology, we disrupted the loci of FOXO genes in lymphoma cell lines and discovered that ablation of FOXO1 (but not FOXO3) was sufficient for upregulation of the surface level of CD20 by 3-fold. Consistently, the complement-dependent cytotoxicity (CDC), induced by rituximab, was significantly improved in cell clones with abrogated expression of FOXO1, but not FOXO3. Importantly, the treatment with pharmacological inhibitor of FOXO1 activity, AS1842856, resulted in increased levels of CD20 on the surface of both lymphoma cell lines and patients-derived chronic lymphocytic leukemia (CLL) cells cultured ex vivo. In order to verify our findings in the animal model, we inoculated SCID mice intravenously with Raji cells, what resulted in the development of lymphoma-like tumors. We demonstrated that mice treated systemically with rituximab, administered at a dose of 10 mg/kg, survived longer when inoculated with sgFOXO1-transduced Raji cells as compared with mice inoculated with control Raji cells (median survival 49 days versus 29 days, respectively). These results confirmed that FOXO1 ablation in lymphoma cells resulted in higher efficacy of rituximab treatment in vivo. Taken together, these results establish FOXO1 as an important determinant of cell response to complement-dependent rituximab-induced cytotoxicity and indicate that FOXO1 inhibitors could be exploited for the therapeutic purposes, in combination with anti-CD20 monoclonal antibodies. Novel FOXO1 inhibitors with improved potency and selectivity are however urgently needed for further exploration of our discoveries in the near future. Acknowledgments: NCN, Poland (grant no: 2013/11/B/NZ5/03240) and H2020 (STREAM project, CSA action, grant no: 692180). Citation Format: Beata Pyrzynska, Abdessamad Zerrouqi, Michal Dwojak, Giulia Morlino, Piotr Zapala, Nina Miazek, Agnieszka Zagozdzon, Kamil Bojarczuk, Malgorzata Bobrowicz, Marta Siernicka, Marcin M. Machnicki, Joanna Barankiewicz, Ewa Lech-Maranda, Przemyslaw Juszczynski, Dinis Calado, Jakub Golab, Magdalena Winiarska. FOXO1 is transcriptional regulator of malignant B-cell surface antigen CD20, the target for therapeutic monoclonal antibodies [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2017 Oct 1-4; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2018;6(9 Suppl):Abstract nr B17." @default.
• W2912389092 created "2019-02-21" @default.
• W2912389092 creator A5002171069 @default.
• W2912389092 creator A5020023524 @default.
• W2912389092 creator A5027478554 @default.
• W2912389092 creator A5029573290 @default.
• W2912389092 creator A5029918677 @default.
• W2912389092 creator A5031962066 @default.
• W2912389092 creator A5038751267 @default.
• W2912389092 creator A5042426002 @default.
• W2912389092 creator A5045400358 @default.
• W2912389092 creator A5049943311 @default.
• W2912389092 creator A5061408064 @default.
• W2912389092 creator A5063861681 @default.
• W2912389092 creator A5064459044 @default.
• W2912389092 creator A5082007741 @default.
• W2912389092 creator A5086914724 @default.
• W2912389092 creator A5091273058 @default.
• W2912389092 creator A5091733870 @default.
• W2912389092 date "2018-09-01" @default.
• W2912389092 modified "2023-10-12" @default.
• W2912389092 title "Abstract B17: FOXO1 is transcriptional regulator of malignant B-cell surface antigen CD20, the target for therapeutic monoclonal antibodies" @default.
• W2912389092 doi "https://doi.org/10.1158/2326-6074.tumimm17-b17" @default.
• W2912389092 hasPublicationYear "2018" @default.
• W2912389092 type Work @default.
• W2912389092 sameAs 2912389092 @default.
• W2912389092 citedByCount "0" @default.
• W2912389092 crossrefType "proceedings-article" @default.
• W2912389092 hasAuthorship W2912389092A5002171069 @default.
• W2912389092 hasAuthorship W2912389092A5020023524 @default.
• W2912389092 hasAuthorship W2912389092A5027478554 @default.
• W2912389092 hasAuthorship W2912389092A5029573290 @default.
• W2912389092 hasAuthorship W2912389092A5029918677 @default.
• W2912389092 hasAuthorship W2912389092A5031962066 @default.
• W2912389092 hasAuthorship W2912389092A5038751267 @default.
• W2912389092 hasAuthorship W2912389092A5042426002 @default.
• W2912389092 hasAuthorship W2912389092A5045400358 @default.
• W2912389092 hasAuthorship W2912389092A5049943311 @default.
• W2912389092 hasAuthorship W2912389092A5061408064 @default.
• W2912389092 hasAuthorship W2912389092A5063861681 @default.
• W2912389092 hasAuthorship W2912389092A5064459044 @default.
• W2912389092 hasAuthorship W2912389092A5082007741 @default.
• W2912389092 hasAuthorship W2912389092A5086914724 @default.
• W2912389092 hasAuthorship W2912389092A5091273058 @default.
• W2912389092 hasAuthorship W2912389092A5091733870 @default.
• W2912389092 hasConcept C140149449 @default.
• W2912389092 hasConcept C147483822 @default.
• W2912389092 hasConcept C159654299 @default.
• W2912389092 hasConcept C16232356 @default.
• W2912389092 hasConcept C18031839 @default.
• W2912389092 hasConcept C203014093 @default.
• W2912389092 hasConcept C2777701055 @default.
• W2912389092 hasConcept C2777843201 @default.
• W2912389092 hasConcept C2777938653 @default.
• W2912389092 hasConcept C2778384904 @default.
• W2912389092 hasConcept C2778461978 @default.
• W2912389092 hasConcept C2779338263 @default.
• W2912389092 hasConcept C2779725641 @default.
• W2912389092 hasConcept C2780653079 @default.
• W2912389092 hasConcept C2780790343 @default.
• W2912389092 hasConcept C502942594 @default.
• W2912389092 hasConcept C542903549 @default.
• W2912389092 hasConcept C62478195 @default.
• W2912389092 hasConcept C75217442 @default.
• W2912389092 hasConcept C86803240 @default.
• W2912389092 hasConcept C8891405 @default.
• W2912389092 hasConcept C95444343 @default.
• W2912389092 hasConceptScore W2912389092C140149449 @default.
• W2912389092 hasConceptScore W2912389092C147483822 @default.
• W2912389092 hasConceptScore W2912389092C159654299 @default.
• W2912389092 hasConceptScore W2912389092C16232356 @default.
• W2912389092 hasConceptScore W2912389092C18031839 @default.
• W2912389092 hasConceptScore W2912389092C203014093 @default.
• W2912389092 hasConceptScore W2912389092C2777701055 @default.
• W2912389092 hasConceptScore W2912389092C2777843201 @default.
• W2912389092 hasConceptScore W2912389092C2777938653 @default.
• W2912389092 hasConceptScore W2912389092C2778384904 @default.
• W2912389092 hasConceptScore W2912389092C2778461978 @default.
• W2912389092 hasConceptScore W2912389092C2779338263 @default.
• W2912389092 hasConceptScore W2912389092C2779725641 @default.
• W2912389092 hasConceptScore W2912389092C2780653079 @default.
• W2912389092 hasConceptScore W2912389092C2780790343 @default.
• W2912389092 hasConceptScore W2912389092C502942594 @default.
• W2912389092 hasConceptScore W2912389092C542903549 @default.
• W2912389092 hasConceptScore W2912389092C62478195 @default.
• W2912389092 hasConceptScore W2912389092C75217442 @default.
• W2912389092 hasConceptScore W2912389092C86803240 @default.
• W2912389092 hasConceptScore W2912389092C8891405 @default.
• W2912389092 hasConceptScore W2912389092C95444343 @default.
• W2912389092 hasLocation W29123890921 @default.
• W2912389092 hasOpenAccess W2912389092 @default.
• W2912389092 hasPrimaryLocation W29123890921 @default.
• W2912389092 hasRelatedWork W170766043 @default.
• W2912389092 hasRelatedWork W1972354719 @default.
• W2912389092 hasRelatedWork W1998533565 @default.
• W2912389092 hasRelatedWork W2142287416 @default.
• W2912389092 hasRelatedWork W2160420564 @default.
• W2912389092 hasRelatedWork W2164294729 @default.
• W2912389092 hasRelatedWork W2396948201 @default.
• W2912389092 hasRelatedWork W2912389092 @default.

• next